Premium
Serum P‐selectin Level During Controlled Ovarian Hyperstimulation – a Preliminary Report
Author(s) -
Orvieto Raoul,
Badir Walid,
Bar Jacob,
La Marca Antonio,
Ashkenazi Jacob,
Avrech Ori M.,
Fisch Benjamin
Publication year - 2004
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/j.1600-0897.2004.00194.x
Subject(s) - controlled ovarian hyperstimulation , ovarian hyperstimulation syndrome , medicine , andrology , p selectin , l selectin , gynecology , endocrinology , pregnancy , biology , infertility , in vitro fertilisation , platelet , genetics , receptor , platelet activation
Objective: To measure levels of serum P‐selectin in patients undergoing controlled ovarian hyperstimulation (COH) cycles and to determine their possible correlation to COH variables. Setting: Large university‐based infertility and in vitro fertilization unit. Patients: Fourteen consecutive patients undergoing our routine COH protocol for unexplained infertility. Interventions and Main Outcome Measures: Blood was drawn three times during the COH cycle: (1) day 2 or 3 of the menstrual cycle, before gonadotropin treatment (Day‐0); (2) day of or prior to human chorionic gonadotropin (hCG) administration (Day‐hCG); and (3) day of ovulation (Day‐OVU). Serum levels of sex steroids and P‐selectin were compared among the three time points. P‐selectin was measured with a commercial quantitative sandwich immunoassay technique. To reduce interpatient variability, the percent difference between the Day‐0 (non‐stimulated, basal) level and the Day‐hCG and Day‐OVU levels was calculated. Results: P‐selectin level on Day‐hCG was significantly higher than on Day‐0 ( P < 0.05) and non‐significantly higher than on Day‐OVU ( P < 0.12). No significant correlations were observed between serum P‐selectin and patient age, amount of gonadotropins used, or estradiol or progesterone level. Conclusion: The increase in serum P‐selectin level during COH until peak estradiol suggests that COH may potentiate a state of platelet activation which is substantially attenuated after hCG administration.